ScreenerHero

LABT Lakewood-Amedex Biotherapeutics, Inc.

NAS · US · Healthcare · Biotechnology · lakewoodamedex.com
0.8498USD-1.98%Mkt Cap: 2.01M $P/E: —

Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap2.01M USD
Enterprise Value-2.43M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-3.85M USD
Revenue/Share—
Last Price0.8498 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA0.33
EV/Revenue—
P/S—
P/B0.43
EPS (TTM)-9.01
EPS (Forward)—
52W Range
0.76100% of range98.20
52W High98.20 USD
52W Low0.7610 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE195.85%
ROA-798.93%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.94M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-45.26%
Net Debt-4.48M USD
Net Debt/EBITDA0.62
Balance Sheet
Debt/Equity-0.85
Current Ratio7.70
Quick Ratio7.29
Book Value/Sh2.00 USD
Cash/Share1.94 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJun 22, 2026
Analyst Consensus
Rating0.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)12.00 USD
Upside (mean)+1312.1%
Target Range12.00 USD – 12.00 USD
# Analysts1
Ownership
Shares Out.2.37M
Float847.66K
Insiders39.47%
Institutions6.02%
Short Interest
Short Ratio0.0d
Short % Float4.34%
Short % Out.2.24%
Shares Short52.97K
Short (prev mo.)56.25K
Technical
SMA 502.027 (-58.1%)
SMA 2008.338 (-89.8%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)2.30M
Avg Vol (10d)3.81M
Technical Indicators
RSI (14)26.2
MACD-0.3967
MACD Signal-0.3354
MACD Hist.-0.0613
BB Upper2.653 USD
BB Middle1.567 USD
BB Lower0.4811 USD
BB Width138.60%
ATR (14)0.2320 USD
Vol Ratio (20d)3.86x